<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Chemistry</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B8DE35C1-BD77-40C7-A617-698BD33A5AB7"><gtr:id>B8DE35C1-BD77-40C7-A617-698BD33A5AB7</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Sutton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4A2FC59D-8466-44C3-8DAA-64CEF8226EFA"><gtr:id>4A2FC59D-8466-44C3-8DAA-64CEF8226EFA</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Spivey</gtr:surname><gtr:orcidId>0000-0001-5114-490X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1A92AD5A-28CF-4D01-81D6-532BEEE07B30"><gtr:id>1A92AD5A-28CF-4D01-81D6-532BEEE07B30</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Beavil</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C524C63E-0DA7-4161-9769-46974CABC613"><gtr:id>C524C63E-0DA7-4161-9769-46974CABC613</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Leatherbarrow</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601116"><gtr:id>B83A94A1-5231-4110-A61A-28A5E7E46C86</gtr:id><gtr:title>A generic approach to disrupting protein-protein interactions application to the hIgE-FceRI interface</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601116</gtr:grantReference><gtr:abstractText>Asthma and other allergic manifestations are the result of a complex cascade of events at the molecular level initiated by the detection of an allergen (from pollen, dust mites etc.) by a protein in the blood called IgE, which culminates in the release of toxic inflammatory agents (resulting in airway inflamation etc.). This research is aimed at the rational development of molecules that are able to prevent the docking of IgE to its receptor protein on the surface of certain cells, thereby preventing the generation of the harmful inflammatory agents following activation by allergens. The molecules identified as being effective for blocking this key protein-protein binding event are expected to constitute exciting leads for the development of anti-allergic drugs. Moreover, since related protein-protein binding events are widespread in human disease processes, an increased level of understanding of the manner in which these interactions can be disrupted is likely to be of significant therapeutic value in many areas of medicine and healthcare.</gtr:abstractText><gtr:technicalSummary>The IgE-FceRI protein-protein interaction (PPI) is central to the allergic cascade associated with asthma and all other allergic manifestations. We propose to use Solid Phase (SP) parallel synthesis to prepare a series of novel antagonists of this PPI, to kinetically characterise these molecules using a series of biophysical assays and to subject promising leads to parallel co-crystallisation with recombinant protein. The antagonists are conformationally constrained cyclic peptides, based on known peptide antagonists, but incorporating diphenylethylenes and biphenyls as backbone linking units and arrays of novel biphenyl amino acids at key positions aready identified as binding hot-spots by mutagenesis. In addition to being predisposed towards PPI binding, these compounds are expected to display high metabolic/proteolytic stability (as the result of decreased conformational mobility) and superior ADMET and crystallisation properties relative to conventional cyclic peptides (e.g. disulfide constrained). The chemistry program will be integrated closely to the medium-throughput binding assays based on ELISA, FRET, SPR and cellular secretion technologies and the most promising binders will be subject to semi-automated protein co-crystallisation using nanolitre volumes. The expected outcome will be the identification of a novel series of potent antagonists of this important interaction and associated high resolution structural/mode of action data which should provide a strong platform for subsequent drug design. Additionally, the specific data obtained for this protein-protein interface is expected to provide important insights of generic value for the understanding of the manner in which small molecules interact with large and complex protein surfaces at the molecular level. This information should be invaluable for advancing strategies for addressing the designed disruption of therapeutically significant PPIs.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-08-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>670095</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MTA with Novartis</gtr:description><gtr:id>66B728DE-D8D3-472D-8011-6D5037EEF867</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>MxvzjDZujJX-1</gtr:outcomeId><gtr:partnerContribution>screening expertise</gtr:partnerContribution><gtr:piContribution>Novartis are testing some of our compounds in their IgE screens</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Medicinal Chemistry UCB Pharma</gtr:department><gtr:description>MTA with UCB</gtr:description><gtr:id>94260FBE-A110-467E-8EC2-63D0038C8175</gtr:id><gtr:impact>Currently via confidential reports</gtr:impact><gtr:outcomeId>atuXTqAB8Z6-1</gtr:outcomeId><gtr:partnerContribution>Provision of a range of screening assays and analytical techniques</gtr:partnerContribution><gtr:piContribution>We have provided samples of synthesised antagonists including aspercyclide A C19 methyl ether and participated in various conferences with scientists from UCB</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Imperial College Institute of Chemical Biology (ICB) Studentship Scheme</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>16C237C9-C1D8-4AEB-A79A-AD39751ECB82</gtr:id><gtr:outcomeId>Pse4FKNechR0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie FP7-PEOPLE-2009-IEF</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:fundingRef>253556 TSAsperA</gtr:fundingRef><gtr:id>55829E01-9F1B-4189-BB01-F414C84E86BF</gtr:id><gtr:outcomeId>79005F8F6870</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CE462E73-0055-4A1F-8653-B8D67038388D</gtr:id><gtr:title>Synthesis and incorporation into cyclic peptides of tolan amino acids and their hydrogenated congeners: construction of an array of A-B-loop mimetics of the Ce3 domain of human IgE.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc41aff7cd0abbb3e09ecff785f03ad0"><gtr:id>cc41aff7cd0abbb3e09ecff785f03ad0</gtr:id><gtr:otherNames>Offermann DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>pm_12513_23_22397517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85E4B103-FED6-4681-B627-E4678783E33E</gtr:id><gtr:title>Synthesis of the C19 methyl ether of aspercyclide A via germyl-Stille macrocyclisation and ELISA evaluation of both enantiomers following optical resolution.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b9baf75965bce08cbac00451a852fd"><gtr:id>42b9baf75965bce08cbac00451a852fd</gtr:id><gtr:otherNames>Carr JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>rq97vERpJpM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70FF952B-11E5-4D07-8F47-DA62199BD642</gtr:id><gtr:title>Total synthesis of (+/-)-aspercyclide A and its C19 methyl ether.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b9baf75965bce08cbac00451a852fd"><gtr:id>42b9baf75965bce08cbac00451a852fd</gtr:id><gtr:otherNames>Carr JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>doi_53d02c02c47041ae</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B607C649-FFD8-49A6-9DF2-5EDA52CD9946</gtr:id><gtr:title>Enantioselective synthesis of (+)-aspercyclide A</gtr:title><gtr:parentPublicationTitle>Tetrahedron Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3f2c833b238fdce89602bbeb2a8daaa"><gtr:id>a3f2c833b238fdce89602bbeb2a8daaa</gtr:id><gtr:otherNames>Sejberg J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56d96706348f24.43633989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>057E576D-0FB3-4AD1-91C3-AA307AB0A949</gtr:id><gtr:title>Development of small molecules to target the IgE:FceRI protein-protein interaction in allergies.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9e12b0b3bf56fb1ee7affe8bbaa91df"><gtr:id>a9e12b0b3bf56fb1ee7affe8bbaa91df</gtr:id><gtr:otherNames>Smith LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>56d9670654a5b5.25188074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>509224DF-3B37-4130-BF91-3B74845C34D4</gtr:id><gtr:title>Stereocontrolled Formation of Styrenes by Pd(0)-catalyzed Cross-coupling of Photoactivated (
 
 )-Alkenylgermanes with Aryl Bromides</gtr:title><gtr:parentPublicationTitle>Chemistry Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/284d7df404076b3f9f156bb74e88e699"><gtr:id>284d7df404076b3f9f156bb74e88e699</gtr:id><gtr:otherNames>Tseng C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>546383ff3c7de4.16723978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A949252-2091-4237-A75A-FB732611DF9E</gtr:id><gtr:title>A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0306b0f65fa4e0c34091c5f4114bb99"><gtr:id>b0306b0f65fa4e0c34091c5f4114bb99</gtr:id><gtr:otherNames>Spivey AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>pm_55f944a944acef462</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601116</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>